Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03827668 | A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS | PHASE1 | COMPLETED | 15 | — | — | Feb 7, 2019 | Apr 29, 2019 | May 20, 2020 | 1 | United States |
Maximum observed concentration (Cmax) derived from plasma
Area under the plasma concentration-time profile derived from plasma from time 0 to time tau, the dosing interval (AUCtau), where tau=24 for QD dosing.
Maximum observed concentration (Cmax) derived from plasma
Area under the plasma concentration-time profile derived from plasma from time 0 to time tau, the dosing interval (AUCtau), where tau=24 for QD dosing.
| Arm | Type | Description |
|---|---|---|
| Single arm | EXPERIMENTAL | The study will have only one study group in a fixed-sequence type of design with two periods |
| Name | Type | Description |
|---|---|---|
| PF-06650833 alone | DRUG | In Period 1, Days 1-5, participants will receive PF-06650833 once daily alone. |
| PF-06651600 alone | DRUG | In Period 2, Days 1-7, participants will receive PF-06651600 once daily alone. |
| PF-06650833 together with PF-06651600 | DRUG | In Period 2, Days 8-12, participants will receive PF-06650833 once daily together with PF-06650833 once daily. |
Inclusion Criteria: * Male and female participants must be 18 to 55 years of age, inclusive, at the time of signing the informed consent document (ICD) * Male and female participants who are healthy as determined by medical evaluation including medical history, physical examination, including blood...